Conditions: Type 2 Diabetes Mellitus
Keywords: Type 2 Diabetes Mellitus Nateglinide Pancreatic beta cell function
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 88
Healthy volunteers: no

Brief summary:
This multi-center, randomized controlled study aims to evaluate the durability and efficacy of nateglinide therapy for long term glycemic control compared with glimepiride.

Detailed description:
Selected patients will be randomly assigned to receive nateglinide or glimepiride.

Previous treatment with oral antidiabetic drugs (metformin, a-glucosidase inhibitor, nateglinide or sulfonylurea) will be discontinued. After a 1 month wash-out period (if 6.5 ≤ HbA1c ≤ 8.5), patients will take randomly assigned drugs for 24 months.

Patients will be met by the trial investigator every 3 months following randomization. At each visit, patients whose HbA1c is \> 8.0% will be retested 2 weeks later, and if the retested HbA1c is also above 8.0%, those patients will be withdrawn considering monotherapy failure. We will evaluate the durability of nateglinide in comparison with that of glimepiride based on the withdrawal rate.

Arms:
arm 1: Nateglinide 90\~120mg three times a day arm 2: Glimepiride 1\~2mg once a day

Interventions: intervention 1: Nateglinide intervention 2: Glimepiride
Intervention descriptions: intervention 1: Nateglinide 90\~120mg three times a day intervention 2: Glimepiride 1\~2mg once a day

Protocol document: